Key result
Prasugrel significantly reduced the overall risk of MI compared with clopidogrel (7.4% vs 9.7%; HR 0.76; 95% CI 0.67-0.85; P<0.0001) in patients with ACS undergoing PCI.
Why the study?
Does prasugrel reduce the risk of myocardial infarction compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
RCT (n=13,608)
Yes
Does prasugrel reduce the risk of myocardial infarction compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Effect estimate: HR 0.76 (95% CI 0.67 to 0.85)
Absolute Event Rate: 7.4% vs 9.7%
p-value: p=<0.0001
In patients with ACS undergoing PCI, prasugrel significantly reduces the risk of both spontaneous and procedure-related myocardial infarctions compared to clopidogrel.
No takes yet. Share an insight, caveat, or question.
Supports prasugrel preference over clopidogrel in ACS-PCI; confirms benefit across spontaneous and procedure-related MI subtypes.
Morrow et al. (2009) conducted an RCT in Acute coronary syndrome undergoing percutaneous coronary intervention (n=13,608). Prasugrel vs. Clopidogrel was evaluated on Overall risk of MI (HR 0.76, 95% CI 0.67 to 0.85, p=<0.0001). Prasugrel significantly reduced the overall risk of MI compared with clopidogrel (7.4% vs 9.7%; HR 0.76; 95% CI 0.67-0.85; P<0.0001) in patients with ACS undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: